넳 넲

2025-07-10

More >>

2024-09-28

More >>

2024-05-10

More >>
  • Impress at the 3rd Hepatitis Innovation Forum

    On March 23rd, the third Hepatitis Innovation Forum, hosted by the China Foundation for Health and Development, took place in Beijing. The forum attracted top experts from basic research, clinical research, and innovative pharmaceutical companies from all over the country to gather and discuss the development trends and challenges in the field of liver disease treatment. 

    넶404 2024-03-27

2024-03-27

More >>
  • Hepatitis B Drug HT-101 (siRNA) Receives FDA Clinical Approval

    On February 2, 2024, Suzhou Starlight Kunze Biopharmaceutical Co., Ltd. (hereinafter referred to as "Starlight Kunze") announced that its hepatitis B drug candidate HT-101 (siRNA) has received approval from the U.S. FDA to proceed directly to Phase Ib clinical trials for chronic hepatitis B virus infection.

    넶603 2024-02-04

2024-02-04

More >>

2023-05-24

More >>

2024-11-08

More >>

2025-04-01

More >>

2025-11-12

More >>

2025-09-23

More >>

2026-01-19

More >>

2026-05-6

More >>

2026-05-15

More >>

2026-05-30

More >>

2026-05-28

More >>

2026-07-02

More >>

2026-10-26

More >>

2026-11-10

More >>
  • Hepa Thera's Breakthrough Achievement

    Breakthrough achievement – Hepa Thera announced the latest data of its new-generation functional cure product HT-101 + HT-102 at the 2026 American Association for the Study of Liver Diseases Annual Conference.

    넶81 2026-11-10